Phase 2
N=405
Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome
Metabolic Syndrome
Bottom Line
View on ClinicalTrials.gov: NCT02503865 ↗Enrolled (actual)
405
Serious AEs
15.7%
Results posted
Nov 2015
Primary outcome: Primary: Blood Glucose Level — 6.05; 6.43; 4.58; 14.5 mmole/L
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin (Drug); "Analimentary detoxication" (Dietary_supplement)
- Age
- Adult, Older Adult · 25+ yrs
- Sex
- All
- Sponsor
- Nazarbayev University
- Primary completion
- Dec 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Blood Glucose Level |
6.05; 6.43; 4.58; 14.5; 14.6; 5.3 | — |
| PRIMARY Systolic/ Diastolic Blood Pressures (mm Hg) |
151.2; 152.1; 121.1; 94.1; 96.9; 79.9 | — |
| SECONDARY Lipid Profile |
5.22; 5.35; 4.9; 0.76; 0.75; 1.22 | — |
| SECONDARY Immunoassay Hormones in Blood |
22.9; 23.2; 6.5 | — |
| SECONDARY Immunoassay Cortisole in Blood |
743.8; 751.2; 445.3 | — |
Summary
Metabolic syndrome: aetiology, pathogenesis, diagnosis, clinical management and prognosis
Eligibility Criteria
Inclusion Criteria
- written consent form
- age> 25 years
- skinfold thickness > 0, 7 cm BP> 130/85 mm Hg or a patient on antihypertensive medications fasting blood glucose > 6.1 mmole/L, or 2-hour postprandial glucose level > 11.1 mmole/L / or a patient with type 2 diabetes blood cholesterol > 5.6 mmole/L possibility of treatment > 6 months follow-up > 1 year
Exclusion Criteria
- complete immobilization of a patient (paresis /paralysis)
- patients with severe concomitant diseases of the kidneys and (or) of the liver
- early post-operative condition
- mental illness
- pregnancy
- persons who are in prison
- persons who are in military Armed Forces
Data sourced from ClinicalTrials.gov (NCT02503865). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.